Mounjaro Tops India’s Drug Market | Weight-Loss Boom, Big Pharma Battle Ahead

India’s weight-loss drug market is witnessing an unprecedented surge. Eli Lilly’s Mounjaro has shot to the No.1 spot, recording ₹100 crore in sales in October alone and over ₹333 crore since its launch in March. The therapy, used for diabetes and obesity management, has sparked a new race in the pharma space. With Novo Nordisk’s Ozempic recently approved and Wegovy already making inroads, the stage is set for a big pharma face-off in India’s rapidly expanding metabolic treatment market.